Literature DB >> 16254962

Molecular characterization and genetic variation of the VP7 gene of human rotaviruses isolated in Paraguay.

Gabriel Ignacio Parra1, Karin Bok, Vicente Martínez, Graciela Russomando, Jorge Gómez.   

Abstract

Rotavirus is the main cause of acute diarrhea in infants and young children worldwide. In Paraguay, acute diarrhea ranks fourth among the causes of mortality in children under 4 years of age. Rotavirus was detected in 93 out of 410 patients admitted to three main hospitals in Asunción, Paraguay from August 1998 to August 2000. Samples from 64 patients were analyzed by RT-PCR for G and P typing. G4P[8] (46.9%; 30/64) was the most common strain detected, followed by G9P[8] (17.2%; 11/64) and G1P[8] (10,9%; 7/64). Since G4 was predominant during the epidemiological peaks of 1998 and 1999, four samples were sequenced and all grouped into sublineage Ic. This sublineage was reported for the first time in 1998 in Argentina, southern border of Paraguay, and it was shown to be responsible for the increased prevalence of G4 during the epidemiological season of 1998 in that country. In addition, Paraguayan G1 strains grouped in different lineages (I and II). However, G9 was predominant during the rotavirus epidemiological peak of 2000, and phylogenetic analysis of five samples grouped into a common emergent/reemergent lineage that circulates worldwide. Since vaccination could reduce the severity and the number of cases of rotavirus disease, this study suggests that a vaccine containing recently isolated variants of the most prevalent types (G1-G4) together with the emerging G9 type, might be sufficient to elicit a protective immune response against the rotavirus types circulating currently in Paraguay. Copyright (c) 2005 Wiley-Liss, inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254962     DOI: 10.1002/jmv.20495

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between human rotaviruses circulating in Belgium and rotaviruses in Rotarix and RotaTeq.

Authors:  Mark Zeller; John T Patton; Elisabeth Heylen; Sarah De Coster; Max Ciarlet; Marc Van Ranst; Jelle Matthijnssens
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

2.  Human G9P[8] rotavirus strains circulating in Cameroon, 1999-2000: Genetic relationships with other G9 strains and detection of a new G9 subtype.

Authors:  M D Esona; S Mijatovic-Rustempasic; K Foytich; S Roy; K Banyai; G E Armah; A D Steele; E M Volotão; M M Gomez; M F M Silva; R Gautam; O Quaye; K I Tam; J C Forbi; M Seheri; N Page; J Nyangao; V N Ndze; M Aminu; M D Bowen; J R Gentsch
Journal:  Infect Genet Evol       Date:  2013-06-14       Impact factor: 3.342

3.  Characterization of novel VP7, VP4, and VP6 genotypes of a previously untypeable group A rotavirus.

Authors:  Owen D Solberg; Maria Eloisa Hasing; Gabriel Trueba; Joseph N S Eisenberg
Journal:  Virology       Date:  2009-01-08       Impact factor: 3.616

4.  Comparative analysis of the Rotarix™ vaccine strain and G1P[8] rotaviruses detected before and after vaccine introduction in Belgium.

Authors:  Mark Zeller; Elisabeth Heylen; Sana Tamim; John K McAllen; Ewen F Kirkness; Asmik Akopov; Sarah De Coster; Marc Van Ranst; Jelle Matthijnssens
Journal:  PeerJ       Date:  2017-01-03       Impact factor: 2.984

5.  Human rotavirus strains circulating in Venezuela after vaccine introduction: predominance of G2P[4] and reemergence of G1P[8].

Authors:  Esmeralda Vizzi; Oscar A Piñeros; M Daniela Oropeza; Laura Naranjo; José A Suárez; Rixio Fernández; José L Zambrano; Argelia Celis; Ferdinando Liprandi
Journal:  Virol J       Date:  2017-03-21       Impact factor: 4.099

6.  Symptomatic and subclinical infection with rotavirus P[8]G9, rural Ecuador.

Authors:  Pablo Endara; Gabriel Trueba; Owen D Solberg; Sarah J Bates; Karina Ponce; William Cevallos; Jelle Matthijnssens; Joseph N S Eisenberg
Journal:  Emerg Infect Dis       Date:  2007-04       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.